|
Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation |
Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Papaioannou D, Rafia R, Rathbone J, Stevenson M, Buckley Woods H, Stevens J. Rituximab for the first-line treatment of stage III–IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation. Health Technology Assessment 2012; 16(37): 1-253 Authors' conclusions The addition of rituximab to CVP, CHOP and MCP is likely to be clinically effective in the first-line treatment of stage III–IV FL. The cost per QALY gained is estimated to be < £25,000 for all three comparisons under our base-case assumption and is considerably lower if first-line rituximab maintenance is not assumed. The main uncertainties in terms of influencing the ICER relate to the effectiveness of rituximab retreatment (i.e. resistance) and the effect of salvage treatment in patients previously treated with anthracycline regimens. Assumptions were made and the best evidence identified was used when appropriate and available. Therefore, results have to be interpreted in line with the assumptions made and the quality of the evidence available. Indexing Status Subject indexing assigned by CRD MeSH Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemotherapy Protocolss; Lymphoma, Follicular; Skin Diseases; Technology Assessment, Biomedical Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence NETSCC, Health Technology Assessment, Alpha House, University of Southampton Science Park, Southampton, SO16 7NS UK Tel: +44 23 8059 5586 Email: hta@hta.ac.uk AccessionNumber 32011000783 Date abstract record published 15/06/2011 |
|
|
|